drug
cabazitaxel
Marketedupdated 5mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying cabazitaxel
- phase3A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase3AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- phase2Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
- phase2Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- phase1A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- phase2A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
- phase2A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 27, 2030
~4.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Apr 27, 2031patentUS 10583110*PED4.6y
- Apr 27, 2031patentUS 10716777*PED4.6y
- Apr 27, 2031patentUS 12453712*PED4.6y
- Apr 27, 2031patentUS 8927592*PED4.6y
- Oct 27, 2030method-of-use (U-2753)US 105831104.1y
- Oct 27, 2030method-of-use (U-2856)US 107167774.1y
- Oct 27, 2030method-of-use (U-4334)US 124537124.1y
- Oct 27, 2030method-of-use (U-3200)US 89275924.1y
- Jun 10, 2026patentUS 7241907*PED
- Dec 10, 2025compositionUS 7241907
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that